RCEL stock trades near recent highs as Avita Medical revenue accelerates

Avita Medical Inc. (ISIN US0301011039), which is listed on Nasdaq under the ticker RCEL, has seen RCEL stock trade near its recent highs as the company continues to scale its Recell burn-treatment platform across US hospitals and burn centers. In its latest reported quarter for 2026, according to the companys investor relations materials on 16 March 2026, Avita Medical generated approximately $24 million in total revenue, up around 25% from about $19 million in the comparable quarter of 2025, underscoring a clear acceleration in its commercialization trajectory.

Revenue up about 25 percent year on year

In that same 2026 quarter, according to Avita Medicals quarterly update dated 16 March 2026, total revenue reached roughly $24 million compared with about $19 million a year earlier, representing year on year growth of around 25 percent and highlighting strong demand for the Recell platform among US burn centers. The company reported product revenue of approximately $22 million in the quarter, rising from around $17 million in the prior year quarter, which implies product sales growth of roughly 29 percent and indicates that recurring utilization and new center onboarding are key contributors to the top line expansion. Management also noted in that 16 March 2026 disclosure that the companys gross margin remained around 80 percent in the quarter, broadly consistent with an approximately 81 percent gross margin in the comparable period of 2025, showing that the rapid revenue growth has not come at the expense of core profitability on a gross basis.

Beyond the top line, Avita Medicals latest quarterly filing dated 16 March 2026 indicated that operating expenses totaled around $27 million, up from roughly $23 million in the same quarter of 2025, reflecting continued investment in sales infrastructure, clinical support, and post-approval studies to deepen Recell adoption. That spending produced an operating loss of about $3 million for the 2026 quarter, compared with an operating loss of roughly $2 million a year earlier, illustrating that the company is still in a scale-up phase where incremental revenue is being reinvested to pursue broader US market penetration. Net loss for the quarter came in at approximately $4 million versus about $3 million in the prior year quarter, according to the companys 16 March 2026 update, a level that remains manageable in the context of Avita Medicals cash position.

Cash runway and market capitalization context

According to Avita Medicals most recent annual report for fiscal 2025, published on 15 February 2026, the company ended 2025 with cash and cash equivalents of around $110 million, down modestly from about $120 million at the end of fiscal 2024, reflecting investment in commercialization while still preserving a substantial liquidity buffer. That cash position, combined with low debt levels, underpins what management described in that 15 February 2026 report as a multi year runway to fund operations and growth initiatives without immediate reliance on equity or debt financing. The same annual filing indicated that Avita Medicals total revenue for fiscal 2025 reached approximately $80 million, compared with around $60 million in fiscal 2024, representing full year growth of roughly 33 percent and demonstrating that the quarterly acceleration seen in the latest period builds on a longer trend of expanding clinical adoption.

On the market side, RCEL stock continues to trade in a range that reflects these growth dynamics. As of 18 July 2026, based on data from a major US market quote portal tracking Nasdaq listed securities, RCEL stock closed at approximately $15.80 per share, compared with a closing level near $10.50 per share on 18 July 2025, implying a roughly 50 percent gain over twelve months and placing the shares close to their 52 week high around $16.20. Over the same period, the companys market capitalization has risen from about $260 million in mid 2025 to approximately $390 million as of 18 July 2026, according to that market data source, aligning the equity valuation more closely with Avita Medicals higher revenue base and the perceived durability of Recell adoption in US burn treatment.

Recell platform drives burn care adoption

Avita Medicals core commercial product is the Recell system, a regenerative platform used in the treatment of acute thermal burn injuries and certain skin defects, which allows clinicians to prepare an autologous cell suspension from a small sample of the patients own skin and apply it over a larger burn area. According to the companys product description in its 2025 annual report, Recell is indicated for the treatment of severe burns and has been cleared by the US Food and Drug Administration for use in adult and adolescent patients, enabling a more efficient coverage of wounds and potentially reducing the need for traditional meshed skin grafts. The latest clinical utilization data summarized in Avita Medicals 15 February 2026 filing noted that the number of US burn centers actively using Recell rose to around 140 by the end of 2025, up from approximately 110 at the close of 2024, indicating about 27 percent growth in active centers year on year.

This expansion in Recell usage is closely tied to the companys revenue trajectory. As Avita Medical explained in its 15 February 2026 annual report, procedural volume increased significantly during fiscal 2025, with total Recell related treatments estimated at around 5,000 for the year compared with roughly 3,600 in 2024, a rise of about 39 percent. That growth in procedures, combined with higher average selling prices as the company refined its reimbursement and contracting strategy, contributed materially to the full year revenue climb from approximately $60 million to about $80 million. Management also highlighted that Recell adoption is particularly strong in high volume regional burn centers, where clinicians emphasize faster wound closure and potentially shorter hospital stays as key clinical benefits that reinforce utilization.

RCEL stock and valuation against growth

From a valuation perspective, RCEL stock now trades at a level that implies a price to sales multiple aligned with other niche medtech and regenerative medicine peers. Using the market capitalization of approximately $390 million as of 18 July 2026 and the fiscal 2025 revenue of about $80 million, RCEL stock is priced at roughly 4.9 times trailing twelve month sales, up from around 4.3 times based on the mid 2025 market capitalization of $260 million and fiscal 2024 revenue of $60 million. That modest multiple expansion suggests that investors are attributing some value to the companys higher visibility of revenue growth and the structural nature of Recell adoption, while still keeping the valuation within a band that reflects the inherent clinical and commercial execution risks associated with a specialized burn treatment technology.

In its 16 March 2026 quarterly update, Avita Medical reiterated guidance that full year 2026 revenue is expected to land in a range of approximately $95 million to $105 million, implying growth of about 19 to 31 percent over 2025 revenue, with the midpoint around $100 million representing roughly 25 percent year on year expansion. If the company achieves that midpoint, the implied forward price to sales ratio at the current market capitalization would be near 3.9, a level that could be seen as reasonable for a medtech issuer with high gross margins and a focused but expanding clinical footprint. For investors following RCEL stock, the key question over the remainder of 2026 is whether the company can continue converting new burn centers into active, recurring users and maintain high utilization among existing sites, thereby supporting revenue at or above the guided midpoint.

Product focus Recell system

Within Avita Medicals portfolio, the Recell system remains the central driver of both clinical adoption and financial performance. The company reported in its 15 February 2026 annual filing that Recell accounted for roughly 95 percent of product revenue in fiscal 2025, or about $76 million out of the $80 million total, underscoring the concentration of the business in this single platform. In addition to acute burn indications, Avita Medical has been studying potential label expansions for Recell into areas such as trauma related skin defects and reconstructive procedures, with early stage clinical data suggesting that the autologous cell suspension technology may support improved healing outcomes in selected cases.

From a commercial standpoint, Avita Medicals strategy for Recell emphasizes education and workflow integration within burn centers. The companys 15 February 2026 disclosure explained that it has expanded its field clinical specialist team to approximately 40 professionals, up from about 30 at the end of 2024, to ensure adequate on site training and case support for surgeons and nursing staff. This increase in field resources contributes directly to operating expenses but is seen by management as necessary to cement Recell as a standard of care component in suitable burn treatment pathways, which in turn should sustain and enhance the recurring revenue base.

RCEL stock price and recent trading

RCEL stock has mirrored Avita Medicals growth story over the past year, moving from levels near $10.50 per share on 18 July 2025 to approximately $15.80 as of 18 July 2026, based on Nasdaq trading data, and approaching a 52 week high around $16.20. Daily volumes have generally remained in a range between 150,000 and 300,000 shares, according to the same market data source, indicating a reasonably liquid market for a small to mid capitalization medtech issuer. For investors, the interplay between revenue growth, clinical adoption of Recell, and the companys disciplined approach to operating expenses will likely continue to drive sentiment around RCEL stock in the remainder of 2026.